The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index; 41 of the 84 sources its claims cite were checked for support.
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Open accessAbstract
Arguably, diabetes mellitus is one of the best quantified human conditions. In the past 50 years, the metabolic monitoring technologies progressed from occasional assessment of average glycemia via HbA1c, through episodic blood glucose readings, to continuous glucose monitoring (CGM) producing data points every few minutes. Mathematial models and computer simulation of the human metabolic system became indispensable for the technological progress of diabetes treatment, enabling every step, from assessment of insulin sensitivity via the now classic Minimal Model of Glucose Kinetics, to in silico trials replacing animal experiments, to automated insulin delivery algorithms. In 2007, we introduced a sophisticated model of glucose-insulin dynamics and a computer simulator equipped with a population of N = 300 in silico subjects with type 1 diabetes. In January 2008, the Food and Drug Administration (FDA) accepted this simulator as a substitute to animal trials for the pre-clinical testing of new treatment approaches.
Overview
CoChat Summary
TL;DR
This review traces the development of the UVA/Padova type 1 diabetes simulator from the Minimal Model to an FDA-accepted in silico population of 300 subjects, and its role in enabling automated insulin delivery. It argues that in silico preclinical testing has largely replaced animal trials for artificial pancreas algorithm development and has contributed to clinically deployed systems such as Control-IQ.
Key findings
- The 2007 simulator included N = 300 in silico T1D “subjects”: N = 100 children below age 11, N = 100 adolescents 12–18 years, and N = 100 adults; in January 2008 the FDA accepted it as a substitute for animal trials for preclinical testing of insulin treatments and closed-loop algorithms (Device Master File 1521).
- A 24-hour period of closed-loop control can be simulated in under 2 seconds, but the authors state that good in silico performance does not guarantee in vivo performance and is only a prerequisite to, not a substitute for, clinical trials.
- Refinements added functionality including diurnal insulin sensitivity, dawn phenomenon, glucagon effects, a GLP-1 model, extension from single meal to single day, acetaminophen pharmacokinetics, long-acting insulin, intraperitoneal insulin absorption, replay simulation, and insulin sensitivity assessment; an IP simulator was used in an in silico study of 100 adults and to design a PID controller for IP insulin delivery without meal announcement.
- Legacy: the first wearable AID system, Diabetes Assistant (DiAs), was developed in 2011; Control-IQ was FDA-authorized in 2019 as the “first interoperable, automated insulin dosing controller,” is cleared in over 25 countries, and has over 400,000 users; real-life data from 9,300 users for a year and 21,000 users for four months confirmed performance virtually identical to pivotal trials. A PubMed search found about 555 papers on closed-loop control or AID algorithms since 1979, and by 2023 six proposed algorithms advanced to clinical practice.
Methods
- Narrative review following the development of mathematical models and computer simulation for diabetes treatment, from the Minimal Model of Glucose Kinetics to the UVA/Padova T1D simulator.
- Draws on prior physiological data, including triple tracer mixed meal studies in >200 adults and children, and describes the creation of an in silico population whose parameters cover key in vivo parameter distributions.
- Synthesizes simulator validation, refinements, and utility, including a sample of 30 publications spanning 12 years and a PubMed search of approximately 555 papers; no new primary data or formal meta-analysis are reported.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: this is a narrative review by the simulator’s developers, not a systematic review; the authors state they include only a sample of 30 publications and that it is not possible to review all uses of the simulation environment.
- Evident from the text: the authors declare potential conflicts of interest, including research support, patent royalties, and honoraria from diabetes technology companies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
21 Valid · 6 Not valid · 23 Not checked · 21 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, use of the meal minimal model in conjunction with the triple tracer method permits robust model assessments of indices of insulin action on the periphery (SI) and on the liver (SIL), glucose effectiveness (SG), insulin secretion, and β-cell function (disposition index).[49][50][51][52][53][54][55][56][57][58][59][60][61]”
§ Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility > Modeling Diabetes Control
What the sources say
- Partly supportedcites [49] sourceExperimental — accuracy not yet measured
The Experimental design section (page unavailable) describes meal minimal-model estimates of insulin action and secretion and meal-derived disposition indexes. It does not describe a meal-derived liver insulin-action index (SIL), and it assumes a value for meal-model glucose effectiveness (SG) rather than estimating it. The paper mentions triple-tracer work in a reference, but does not establish that combining it with the meal minimal model yields all the listed indices. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [50] source
- Partly supportedcites [51] sourceExperimental — accuracy not yet measured
The Research Design and Methods section describes meal minimal models estimating insulin sensitivity, glucose effectiveness, insulin secretion, and disposition indexes; it also describes tracer-based measurements of glucose turnover. It does not report a separate index of insulin action on the liver (SIL), and its statement that the tracer approach is virtually model independent concerns glucose-turnover measurements, not the robustness of all the listed model indices. Page numbers were not available in our copy. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [55] sourceExperimental — accuracy not yet measured
The Analytical techniques section (page unavailable) describes use of the oral glucose minimal model with a triple-tracer meal to estimate net insulin sensitivity (SI), and links its estimation to glucose effectiveness through GEZI. It defines SI as a whole-body measure, not a separate peripheral index, and does not describe a distinct hepatic SIL estimate, insulin secretion, or a β-cell disposition index. (LLM, conf=0.88)
- Partly supportedcites [56] sourceExperimental — accuracy not yet measured
The Database and Protocol section describes a triple-tracer meal, and the Tracer Method and Parameter Estimation sections report estimates of insulin sensitivity (SI) and glucose effectiveness (SG). The paper does not establish separate peripheral and liver insulin-action indices (SI and SIL), or model estimates of insulin secretion or β-cell disposition index. It also says that this analysis uses only two of the three tracers. Page numbers were not available in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [57] source
- Partly supportedcites [58] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These updates were based on emerging physiological data related to diurnal patterns of insulin sensitivity, dawn phenomenon, and glucagon effects amongst others.55,[70][71][72]”
§ Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility > Enabling In Silico Pre-clinical Trials
What the sources say
- Partly supportedcites [55] sourceExperimental — accuracy not yet measured
The Abstract and Discussion report diurnal patterns of insulin sensitivity, and the Results and Discussion report meal-related glucagon differences and a possible effect on endogenous glucose production. The Discussion says such findings should inform closed-loop algorithms, but our copy does not address the dawn phenomenon or establish that the cited updates were based on this study. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [70] source
- Not checked — no full text of the sourcecites [71] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“(2) a successful use of AID in high-risk patients, ie, those who experienced frequent hypoglycemia or had hypoglycemia unawareness or history of severe hypoglycemia, 127”
§ Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility > The Legacy of the Type 1 Diabetes Simulator: The Artificial Pancreas
What the sources say
- Partly supportedcites [127] sourceExperimental — accuracy not yet measured
The System components section identifies DiAs as the platform used for the closed-loop system, and the Primary outcomes section reports a significantly greater reduction in hypoglycemia risk with that system than with the control treatment. The Eligibility criteria include hypoglycemia risk and unawareness, but exclude severe hypoglycemia in the preceding three months; our copy does not establish a history of severe hypoglycemia among participants. It also says the final two experimental subjects used inControl instead of DiAs. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the intraperitoneal (IP) absorption of insulin was modeled; 77,78”
§ Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility > Enabling In Silico Pre-clinical Trials
What the sources say
- Supportedcites [77] source
The Conclusions state that the authors proposed and tested models of intraperitoneal insulin absorption in patients with type 1 diabetes. They identify the selected model as a linear two-compartment model for IP absorption. (LLM, conf=0.95)
- Supportedcites [78] source
The Modeling Methodology section states that four compartmental models of intraperitoneal insulin kinetics were tested. The Discussion reports a model identified from intraperitoneal delivery data, supporting the paraphrase that IP insulin absorption was modeled. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“By 2023, six out of these proposed algorithms advanced to systems accepted in the clinical practice: Medtronic 670G/770G, Medtronic 780G, CamAPS FX developed in Cambridge, UK, the French system Diabeloop, Tandem's Control-IQ, and Insulet's Omnipod 5. 112”
§ Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility > Abbreviations
What the sources say
- Supportedcites [112] source
The Summary of Clinical Evidence (p. 7) names all six systems in the claim and reports that each had FDA clearance or approval or CE approval by March 2022. It describes the expansion of commercially available AID systems, supporting their acceptance in clinical practice by 2023. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
27 more claims · 6 with their cited sources checked
Create a free account to see all 71 claims and every source verdict.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 23
- The quote only partly states this claim. 1
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Diagnosis and Classification of diabetes mellitus
(2014) · Diapedia · doi:10.14496/dia..20 · Cited by 3,214
Quantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874 · cited 3×
“31 A novel feature of the model was that insulin action did not emanate from plasma but from a compartment remote from plasma.”
BackgroundSelf-citationDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s5 · Cited by 1,666
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citation
Research works printed but not linked: 3
- Pickup JC, Williams G. Textbook of Diabetes 2. Hoboken, NJ: Blackwell Publishing, 2003.
- Shichiri M, Kawamori R, Yamasaki Y, Inoue M, Shigeta Y, Abe H. Computer algorithm for the artificial pancreatic beta cell. Artif Organs. 1978;2(suppl):247-250.
- 10.2337/dc20-225. · doi:10.2337/dc20-225
Cited by
Laubenbacher, R., Mehrad, B., Shmulevich, I., & Trayanova, N. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00607-6 · Cited by 239
Digital twins and artificial intelligence in metabolic disease research
MOSQUERA-LOPEZ, C. M., & Jacobs, P. G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.019 · Cited by 90
Kovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 64
“Today,thissimulationenvironment is widely usedfor research and regulatory purposes 29 .”
InfluentialSelf-citationKovatchev, B. P., Lobo, B. J., Fabris, C., Ganji, M., Fathi, A. E., Breton, M. D., Kanapka, L. G., Kollman, C., Battelino, T., & Beck, R. W. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0404 · Cited by 37
Self-citationChallenges and opportunities in uncertainty quantification for healthcare and biological systems
Kimpton, L. M., Păun, L. M., Colebank, M. J., & Volodina, V. (2025) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2024.0232 · Cited by 30
“A food and drug administration-approved tool for insulin delivery is based, in part, on mechanistic modelling (using ordinary differential equations (ODEs)) [33].”
Metadata
- Authors
- Cobelli, C., & Kovatchev, B.
- Affiliations
- University of Padua (IT)
- University of Virginia (US)
- Corresponding author
- Cobelli, Claudio
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2023-09-25
- Volume
- 17
- Issue
- 6
- Pages
- 1493-1505
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC10658679
- OpenAlex
- W4387002681
- Semantic Scholar
- 883805574f813d9e3caa9e28701138e5a44af35d
- Cited by
- 46
- References
- 145
- Citations by year
- 2026: 23 · 2025: 16 · 2024: 7
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (RO1 DK 133148)
- European Commission Horizon 2020 (FORGETDIABETES-FET-EU951933)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, UVA/Padova simulator, in silico modeling, glucose-insulin dynamics, continuous glucose monitoring, artificial pancreas, in silico clinical trials, population simulation
- MeSH terms
- Algorithms, Blood Glucose, Computer Simulation, Diabetes Mellitus, Type 1, Glucose, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Blood Glucose Self-Monitoring, Pancreas, Artificial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. https://app.cochat.ai/papers/10.1177/19322968231195081
- The paper
- Cobelli, C., & Kovatchev, B. (2023). Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231195081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.